Patients undergoing noncardiac surgery have been known for many years to be at risk for the development of significant cardiac morbidity and mortality (1) . Such a risk has been found to vary with age, the nature and urgency of the operation, and a list of other general conditions.. This has included the presence of heart failure, recent myocardial infarction, valvular heart disease such as significant aortic stenosis, electrocardiographic abnormalities and ventricular arrhythmias, as well as certain poor medical conditions in particular chronic pulmonary, renal, and hepatic disease. These features were the basis of the stratification of cardiac complications of noncardiac surgery in 1977 by the Goldman risk index (1) . This was an attempt at the development of a systematic approach to the assessment of cardiovascular risk associated with potentially serious noncardiac surgery.
In the years that followed and especially during the 1990s, attention has been drawn increasingly to the possibility that a more precise quantification of the cardiac risk potential of patients may be achieved preoperatively by a spectrum of noninvasive techniques. Such approaches have become legion with varying sensitivities and specificities (2) (3) (4) . They include the evaluation of exercise capacity by treadmill testing, myocardial perfusion imaging by various radioisotopes techniques, and echocardiographic measurement of segmental wall motion abnormalities before and after provocative maneuvers to induce myocardial ischemia as evidence of underlying coronary artery disease. The impact of these noninvasive tests on the practice of cardiology has been far-reaching and continues to increase (4) .
Despite the plethora of these noninvasive techniques and their increasing acceptance in the clinical arena, whether they have contributed meaningfully and substantially to cardiac morbidity and mortality reduction in patients undergoing noncardiac surgery is not certain. On the other hand, there is little doubt that, in individual and selected patients, the approach of risk identification followed by prophylactic therapy must have a beneficial impact on the cardiac complications of noncardiac surgery. Such experiences may not be considered to be entirely valid for defining guidelines for a wider and systematic applicability to larger subsets of patients at risk. The compelling clinical issue is whether there is now sufficient evidence that permits the creation of specific guidelines that may be more generally applicable to the largest numbers of patients who stand to benefit. Undoubtedly, there are 2 aspects to this clinically important issue. The first is to identify the patient at high risk with a high degree of sensitivity and specificity, and the second is to develop a prophylactic regimen that might be effective in reducing the attendant morbidity and mortality risk. Thus, the relevant question here is whether tools are now available to the clinician to reliably and selectively identify the individuals who are at the highest risk for the development of morbid cardiac events (primarily myocardial infarction and death) as complications of noncardiac surgery during the perioperative period. This was the subject of the American Heart Association/American College of Cardiology (AHA/ACC) guidelines reported in 1996. In essence, the document written under the chairmanship of Kim Eagle (4) , summarizes the evidence that supports the notion of stratification of patients at high risk for myocardial in-farction and death during the course of noncardiac surgery.
On the basis of the available data, the AHA/ACC report proposed a complex 8-step approach to preoperative cardiac assessment. It took cognizance of the available data that had a direct bearing on the role of noninvasive testing in defining the group of patients at risk for serious cardiac complications in patients undergoing noncardiac surgery. The focus was on death and myocardial infarction. These guidelines that stemmed from the scrutiny of the available data dealt largely with definition of risk. The paucity of data from randomized studies in prospectively followed patients precluded definitive recommendations as to how the patients may be managed to attenuate the perceived cardiac risk during surgery once the patient at risk has been identified. The report by Eagle and colleagues (4) concluded that &dquo;the overriding theme of these guidelines is that intervention is rarely necessary to lower the risk of surgery. The goal ... is the rational use of testing in the era of cost containment&dquo; (2) . Thus, the lack of therapeutic guidelines accompanying the guidelines for the delineation of cardiac complications left the clinician in a somewhat perplexing quandary as to the ideal approach to reduce the risk on an individual basis. The issues still requiring elucidation include a practical approach to risk identification in a susceptible patient group, the most appropriate and systematic prophylactic treatment that can be validated, and, perhaps most importantly from standpoint of clinical practice, its ability to be applied routinely in a cost-effective manner. Data that bear on these considerations are now becoming available. They are likely to have an impact on cardiac risk assessment in patients undergoing noncardiac surgery and may lead to the delineation of realistic clinical guidelines. (4) . The question arises whether the same rigorous preoperative evaluation is mandatory in patients at a lesser risk who may be further subcategorized by noninvasive exercise techniques. However, the data, controlled and uncontrolled, suggest that the routine preoperative evaluation of such patients by noninvasive techniques, irrespective of their nature, may be cumbersome while being a low-yield approach and not inexpensive when used on a large scale.
It is of interest that the noninvasive tests in common use have an extremely high negative predictive accuracy (90% to 100%) but have a low positive predictive value ranging from 4% to 63% with a mean of 20% (4). For example, in the case of dobutamine stress echocardiography, the negative predictive values for myocardial infarction and death in a number of studies ranged from 93% to 100%, whereas the range for the positive predictive values ranged from 7% to 23% (4). These figures for the same endpoints have been similar for other noninvasive tests including the flow-imaging techniques (4) . Thus, it would appear that noninvasive tests may not be cost effective in the majority of patients in whom they are being used. Their precise use remains to be defined by stringently controlled clinical trials. In the absence of such data, alternative approaches might be considered. One approach that is inexpensive and inherently simple is the prophylactic use of pharmacological agents that have the potential to markedly reduce myocardial infarction and death in patients who may have coronary artery disease undergoing high-risk noncardiac surgery. The most promising data for prophylactic use in this regard are with j3-adrenergic blocking drugs in a variety of clinical syndromes. The available data indicate the possibility that the routine prophylactic use of these drugs in patients identified solely on clinical parameters as being at high risk for myo-cardial infarction and death in the context of noncardiac surgery may lead to a lower cardiac mortality and morbidity.
Mortality and Morbidity Reduction by I3-Adrenergic Blockade
In the setting of significant coronary artery stenosis, sympathetic hyperactivity, as may occur during the induction of anesthesia and during surgery, may acutely induce silent or symptomatic myocardial ischemia (5,6,7). The electrophysiological consequences of sympathetic hyperactivity may also lead to the shortening of the refractory period, increasing ventricular automaticity, and decreasing ventricular fibrillation threshold. Lowering sympathetic influences to the heart (8) attenuates such effects. Therefore, it was not surprising when data revealed that, as a class, (3-adrenergic blocking drugs were effective in reducing mortality in many subsets of patients who manifest arrhythmias and in those at high risk for death from arrhythmic deaths (9-11). For example, (3-blockers were shown to reduce the death rate in survivors of cardiac arrest (12) , in those with congenital long QT interval syndrome (13, 14) , and in selected cases of ventricular tachycardia (15, 16) . These findings have not been from controlled clinical trials. Nevertheless, they are in line with compelling data from a number of randomized, placebo-controlled (3-blocking trials. These findings have shown consistent and significant decreases in mortality, especially in survivors of acute myocardial infarction (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
What have we learned from these (3-blocker trials, from especially those that show the consistent reduction in mortality by (3-blockade in survivors of acute myocardial infarction? In this setting, the reduction in arrhythmia mortality as judged by the reduced incidence of sudden death and total mortality along with the consistent and significant reduction in the incidence of myocardial reinfarction is compelling ( 10, 11, (17) (18) (19) 25) . A number of features of such an effect in this subset of patients are clearly of therapeutic importance. The first is the knowledge that the magnitude of the benefit of (3-blockade in infarct survivors is correlated closely to the degree of reduction in heart rate (21) , which provides a therapeutic endpoint in judging dosage. An important observation from the substudy of the Beta-blocker Heart Attack Trial (BHAT) in postmyocardial infarct survivors indicated that the extent of benefit with respect to mortality increased commensurately with the degree of reduction in left ventricular ejection fraction (26) , essentially lesser degrees of benefit in patients with relatively wellpreserved ventricular function. This is in line with increasing evidence even in patients with manifest cardiac failure that prophylactically administered (3-blockade reduces sudden death and prolongs overall survival by reducing total mortality (27) (28) (29) (30) (31) (32) (33) (34) . Moreover, because the benefit of j3-blockade increases as the ejection fraction falls (a critical determinant of prognosis in patients with ischemic heart disease), it might be reasonable to expect that this mode of therapy may also be equally effective in patients with cardiac disease undergoing noncardiac surgery.
In a study reported by Stone et al. (35) , oral j3-blockers were given 2 hours before surgery to a group of randomized patients with mild hypertension, most of whom had vascular surgery. Control patients not receiving j3-blockers had a higher (28%) incidence of ST-segment depression than those given (3-blockers (2%). In another limited study, metoprolol was given immediately before surgery and then followed with an intravenous agent during the repair of abdominal aortic aneurysm (36) . In our study, there was a 3% incidence of acute myocardial infarction compared with an incidence of 18% for matched controls. The same group in a subsequent report found less intraoperative ischemia in patients treated with oral metoprolol administered before peripheral vascular surgery (37) . Clearly, these were small studies and were not flawlessly controlled. Nevertheless, the data generated are directionally consistent with the sum total of experience reported in the literature that deals with the effects of (3-blockade in patients at risk for development of myocardial infarction with an increase in total mortality as that seen in patients with heart disease requiring noncardiac surgery. Such a background might be helpful in the interpretation of data from controlled clinical trials in this setting in which the effects of prophylactic (3-blockade are being investigated.
Reducing Perioperative Cardiac Risk in Noncardiac Surgery by I3-Blockade: Implications from

Controlled Clinical Trials
A recent issue of The New England Journal of Medicine presented the results of a clinical trial (38) with an accompanying editorial (39) on the effects of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. This trial was a randomized multicenter study but not a blinded one. The primary outcome measure was a composite figure for death from cardiac causes and nonfatal myocardial infarction within 30 days after major vascular surgery in patients at high risk for these sets of adverse events. The hypothesis being tested was that (3-blockade would significantly reduce the primary outcome measure from 30% in the control limb to 15% in the drug-treated limb. The investigators calculated the sample size on the basis of a previous report in which they found a 28% incidence of serious adverse events of cardiac nature in patients who had clinical risk factors as well as a positive ischemic effect on dobutamine echocardiography (40) . The calculated sample size of 266 would have permitted the detection of a reduction of events by 50% with an alpha level of 0.05 and a statistical power of 0.80. A provision was included for an interim analysis.
The risk potential was identified by clinical features as well as standardized criteria derived from the results of dobutamine echocardiographic analysis of segmental wall motion abnormalities (41) . The trial was prematurely stopped when an interim analysis showed a highly statistically significant beneficial effect of /3-blockade compared with the group given standard medical care. The study population that formed the basis of the investigators' report (38) was derived from a total of 1,351 patients screened of whom 846 patients were found to have 1 or more risk factors with 173 patients with a positive dobutamine echocardiogram. Fifty-nine patients of this group were randomized to (3-blockade and 53 assigned in a randomized manner to standardized medical care. Excluded were 53 patients who were already taking (3-blockers and another 8 patients because they had extensive segmental wall motion abnormalities at rest or after stress testing. The initial dose of bisoprolol was 5 mg for the first week and increased to 10 mg daily during the second week if the heart rate remained over 60 beats per minute. The target heart rate was less than 70 beats per minute. The final dose of the drug was continued up to 30 days. Dose adjustments were made during all phases of the study relative to changes in heart rate and blood pressure.
The results of the study, among a handful of its kind, are clearly of major importance. It was found that at the termination of the study, there were 2 deaths on bisoprolol (3.4%) and 9 deaths in the standard care group ( 17%; P = .02). Nonfatal infarctions were found in 9 patients in the standard care group (17%) and I patient in the bisoprolol group (P < .001). The prirnary outcome measure of death from cardiac causes or nonfatal infarction occurred in 2 patients who had been on bisoprolol (3.4%) compared with 18 patients in the standard care group (34%, P < .001).
Despite the fact that the trial was not conducted in a blinded fashion, the data are compelling and are in line with the previously reported effects on (3-blockade, not only in the setting of patients undergoing noncardiac surgery (42, 43) , but in the wider spectrum of patients who are at risk of dying or the development of myocardial infarction as discussed above. The investigators comment on the somewhat dramatic nature of their findings but, as they indicate, theirs was a highly selected group on the basis of abnormalities noted on dobutamine echocardiography.
It is known that (3-blockers exert a greater salutary effect on mortality as the ventricular function declines (25, 26) and presumably as the severity of ischemia increases as has been noted in previous (3-blocker trials (44) (45) (46) (47) . The investigators emphasize the importance of risk stratification in the demonstration of the beneficial effect of (3-blockade in this context. On the other hand, they do yield to the notion of entirely omitting preoperative noninvasive cardiac testing and prescribing (3-blockade for all patients with clinical risk factors scheduled for high-risk vascular as well as other forms of noncardiac surgery. Appropriately, Lee (39) has emphasized this further in the accompanying editorial.
Whereas the data in Poldermans' study (40) have been derived from a high-risk group, it may not be justifiable to conclude that patients at lesser risk will not benefit from prophylactic (3-blocker therapy in this setting. It is possible that the degree of benefit may be smaller, but the overall impact may be sufficient to warrant the institution of prophylactic therapy to most, if not all, patients in whom (3-blockade is not contraindicated. The approach is simple, inexpensive, and with added benefit in terms of preventing myocardial infarction and death. Beta-blockers are known to prevent the development of atrial fibrillation and the slowing of ventricular rate when the arrhythmia in this setting is inevitable. This has been well shown in the case of the development of atrial fibrillation in the perioperative phase of cardiac surgery (48) . Perhaps the largest tangible benefit from the approach is that such a simple but effective approach may obviate the necessity for costly noninvasive testing in a sizeable fraction of the patient population undergoing high risk surgery. However, the data reported by Pondermals et al. (39) should not leave us with a sense of complacency, as a number of unanswered questions remain. Clearly, it is necessary to define further on the basis of purely clinical criteria which patients might not benefit from prophylactic therapy with j3-blockade. This may avoid the use of unnecessary therapy. Should (3-blockers be given routinely to patients undergoing emergency surgery as is the developing practice in some centers in the U.S.? Pondermals and colleagues (39) elected to administer (3-blocker therapy for at least 2 weeks before and 2 weeks after surgery. No rationale for such a period has been offered. Might it be possible to derive similar outcome benefits from a shorter preoperative period of drug administration? The optimal periods of treatment before and after surgery remain to be defined. We continue to grapple with these and other related issues knowing that only stringently controlled clinical trials of adequate statistical and logistic designs can resolve this issue. In view of this, it seems safe to conclude that (3-blockers have a seemingly class-action effect for the reduction of morbidity and mortality in patients undergoing noncardiac surgery.
Conclusions
It is now well established that many patients undergoing noncardiac surgery develop cardiac complications, particularly myocardial infarction and death of cardiac origin, during the perioperative period. For many years, patients at risk for these complications were identified by clinical indices. The advent of noninvasive approaches in recent decades has led to the widespread use of such tests, especially imaging techniques and echocardiography, combined with exercise testing or pharmacological provocations to exclude myocardial ischemia. Such tests have a high negative but a very low positive predictive accuracy for cardiac complications during noncardiac surgery. To date, there have not yet been standardized therapeutic approaches to patients who have positive noninvasive tests performed before surgery. However, a number of lines of evidence including that from a controlled clinical trial have suggested that perioperative administration of (3-blockade may be highly effective in reducing the incidence of death and myocardial in-farction in patients at high risk for these complications during or after surgery. These data, if confirmed by larger trials with a careful attention to the manner in which the prophylactic therapy is administered in terms of its duration, dosing, and withdrawal following surgery, may have major implications for future guidelines in this setting. The trial results suggest the possibility that patients selected on clinical indices may routinely be offered preoperative 0-blockers rather than undergoing a battery of noninvasive testing that may need to be reserved for a minority of patients. These possibilities can only be vindicated by stringently controlled observations of adequate trial designs and should be undertaken with a priority. Pending the outcome of such trials, the routine use of ¡3-blockers in this setting may be a desirable therapeutic goal in the absence of contraindications. 
